Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
Open Access
- 8 May 2020
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 14 (8), 1881-1897
- https://doi.org/10.1002/1878-0261.12706
Abstract
Although there are molecularly distinct subtypes of prostate cancer, no molecular classification system is used clinically. The ribonucleotide reductase small subunit M2 (RRM2) gene plays an oncogenic role in many cancers. Our previous study elucidated comprehensive molecular mechanisms of RRM2 in prostate cancer (PC). Given the potent functions of RRM2, we set out to determine whether the RRM2 signature can be used to identify aggressive subtypes of PC. We applied gene ontology and pathway analysis in RNA‐seq datasets from PC cells overexpressing RRM2. We refined the RRM2 signature by integrating it with two molecular classification systems (PCS and PAM50 subtypes) that define aggressive PC subtypes (PCS1 and luminal B) and correlated signatures with clinical outcomes in six published cohorts comprising 4,000 cases of PC. Increased expression of genes in the RRM2 signature was significantly correlated with recurrence, high Gleason score, and lethality of PC. Patients with high RRM2 levels showed higher PCS1 score, suggesting the aggressive PC feature. Consistently, RRM2‐regulated genes were highly enriched in the PCS1 signature from multiple PC cohorts. A simplified RRM2 signature (12 genes) was identified by intersecting the RRM2 signature, PCS1 signature, and the PAM50 classifier. Intriguingly, inhibition of RRM2 specifically targets PCS1 and luminal B genes. Furthermore, 11 genes in the RRM2 signature were correlated with enzalutamide resistance by using a single‐cell RNA‐seq dataset from PC circulating tumor cells (CTCs). Finally, high expression of RRM2 was associated with an immunosuppressive tumor‐immune microenvironment in both primary and metastatic prostate cancer using CIBERSORT analysis and LM22, a validated leukocyte gene signature matrix. These data demonstrate that RRM2 is a driver of aggressive prostate cancer subtypes and contributes to immune escape, suggesting that RRM2 inhibition may be of clinical benefit for patients with PC.Keywords
This publication has 52 references indexed in Scilit:
- Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA RepairCell, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2Proceedings of the National Academy of Sciences of the United States of America, 2011
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective studyThe Lancet Oncology, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targetsInternational Journal of Cancer, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- ToppGene Suite for gene list enrichment analysis and candidate gene prioritizationNucleic Acids Research, 2009
- Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate CancerJNCI Journal of the National Cancer Institute, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005